This study identified four potential drug targets for IBS: P2RY14, SLC5A6, ATRAID, and IL1RL1, based on several MR methods, including IVW, MR-Egger, weighted median, weighted mode, simple mode, and a horizontal pleiotropy test. Here, SLC5A6 is linked to irritable bowel syndrome.